Maksan toiminta


  1. Loomis D. et al. (2016) Carcinogenicity of drinking coffee, mate, and very hot beverages. Lancet Oncol, 17(7):877-878.
  2. Bravi F. et al. (2007) Coffee drinking and hepatocellular carcinoma risk: a meta-analysis.Hepatol, 46:430-435.
  3. Larsson S.C. et al. (2007) Coffee consumption and liver cancer: a meta-analysis.Gastroenterol, 132:1740-1745.
  4. Bravi F. et al. (2013) Coffee reduces risk for hepatocellular carcinoma: An updated meta-analysis.Clin Gastro and Hepatol, 11:1413-1421.
  5. Bravi F. et al. (2017) Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies. Eur J Cancer Prev, 26(5): 368-377.
  6. Saab S. et al. (2014) Impact of coffee on liver disease a systematic review.Liver Int, 34(4):495-504.
  7. Goh G.B. et al. (2014) Coffee, alcohol, and other beverages in relation to cirrhosis mortality: the Singapore Chinese Health Study. Hepatol, 60:661-9.
  8. Wadhawan M. and Anandt A.C. (2016) Coffee and Liver Disease. J Clin Exp Hepatol, 6(1): 40–46.
  9. Walton H.B. et al. (2013) An epidemiological study of the association of coffee with chronic liver disease. Scot Med J, 58(4):217-222.
  10. Gressner O.A. (2009) About coffee, cappuccino and connective tissue growth factor – or how to protect your liver!? Enviro Toxicol & Pharmacol, 28(1):1-10.
  11. Modi A.A. et al. (2010) Increased caffeine consumption is associated with reduced hepatic fibrosis.Hepatol, 51:201-209.
  12. Catalano D. et al. (2010) Protective role of coffee on non-alcoholic fatty liver disease (NAFLD). Dig Dis & Sci, 55(11):3200-3206.
  13. Birerdinc A. et al. (2012) Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol & Therapeu, 35(1):76-82.
  14. Molloy J.W. et al. (2012) Association of coffee and caffeine consumption with fatty liver disease, non-alcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatol, 55(2):429-36.
  15. Gutierrez-Grobe Y. et al. (2012) High coffee intake is associated with lower grade non-alcoholic fatty liver disease: the role of peripheral antioxidant activity. Annals Hepatol, 11(3):350-355.
  16. Bambha K. et al. (2014) Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver Int, 34(8):1250-8.
  17. Wijarnpreecha K. et al. (2017) Coffee consumption and risk of non alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastro Hepatol, 29(2):e8-e12.
  18. Shen H. et al. (2016) Association between caffeine consumption and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Therap Adv Gastro, 9(1):113-20.
  19. Hodge A. et al. (2017) Coffee intake is associated with a lower liver stiffness in patients with non-alcoholic fatty liver disease, hepatitis C and hepatitis B. Nutrients, 9(1):56.
  20. Chen Y.P. et al. (2019) A systematic review and a dose-response meta-analysis of coffee dose and non-alcoholic fatty liver disease. Clin Nutr, 38(6):2552-255.
  21. EFSA (2015) Scientific Opinion on the Safety of Caffeine. EFSA J, 13(5):4102.
  22. Freedman N.D. et al. (2009) Coffee intake is associated with lower rates of liver disease progression in chronic Hepatits-C. Hepatol, 50:1360.
  23. Costentin C.E. et al. (2011) Association of caffeine intake and histological features of chronic hepatitis C.J Hepatol, Volume 54; 1123-1129.
  24. Sasaki Y. et al. (2014) Effect of caffeine containing beverage consumption on serum alanine aminotransferase levels in patients with chronic hepatitis C virus infection: a hospital based cohort study. PLoS One, 8(12):e83382.
  25. Gressner O.A. (2009) Less Smad2 is good for you? A scientific update on coffee’s liver benefits. Hepatol, 50, 970-978.
  26. Gressner O.A. et al. (2009) Identification of paraxanthine as the most potent caffeine-derived inhibitor of connective tissue growth factor expression in parenchymal cells. Liver Int, 29(6):886-897.
  27. Muriel P. et al. (2010) Coffee and liver disease. Fitoterapia, 81:297-305.
  28. Romualdo G.R. et al. (2019) Drinking for protection? Epidemiological and experimental evidence on the beneficial effects of coffee or major coffee compounds against gastrointestinal and liver carcinogenesis. Food Res Int, 123:567-589.
  29. Inoue M. and Tsugane S. (2019) Coffee Drinking and Reduced Risk of Liver Cancer: Update on Epidemiological Findings and Potential Mechanisms. Curr Nutr Rep, 8(3):182-186.
  30. Salomone F. et al. (2017) Molecular Bases Underlying the Hepatoprotective Effects of Coffee. Nutrients, 9(1):85.
  31. Blachier M. et al. (2013) ‘The burden of Liver Disease in Europe: A Review of Available Epidemiological Data’ Available at:
  32. Williams R. et al. (2015) Liver disease in the UK: Startling findings & urgent need for action. J Hepatol, 63:297–299
  33. World Cancer Research Fund (2012) Diet Nutrition, Physical Activity and Liver Cancer.  Available at:
  34. Ferlay J. et al. (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer, 46(4):765–81.
  35. Bray F. et al. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin, 68(6):394-424.
  36. Setiawan V.W. et al. (2015) Association of Coffee Intake with Reduced Incidence of Liver Cancer and Death from Chronic Liver Disease in the US Multiethnic Cohort. Gastroenterol, 148(1):118-125.
  37. Bamia C. et al. (2015) Coffee, tea and decaffeinated coffee in relation to hepatocellular carcinoma in a European population: multicentre, prospective cohort study. Int J Cancer, 136(8):1899-908.
  38. Petrick J.L. et al. (2015) Coffee Consumption and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma by Sex: The Liver Cancer Pooling Project. Cancer Epidemiol Biomarkers Prev, 24(9):1398-406.
  39. Lai G.Y. (2013) The association of coffee intake with liver cancer incidence and chronic liver disease mortality in male smokers. Br J Canc 109:1344–1351.
  40. Leung W.W. et al. (2011) Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case-control study. .J Epidemiol & Comm Health, 65:556-558.
  41. Jang E.S. et al. (2013) The effect of coffee consumption on the development of hepatocellular carcinoma in hepatitis B virus endemic area. Liver Int, 33(7):1092-1099.
  42. Kennedy O.J. et al. (2017) Coffee, including caffeinated and decaffeinated coffee, and the risk of Hepatocellular carcinoma: a systematic review and dose-response meta-analysis. BMJ Open, 10.1136/bmjopen-2016-013739.
  43. Wiltberger G. et al. (2019) Protective effects of coffee consumption following liver transplantation for hepatocellular carcinoma in cirrhosis. Aliment Pharmacol Ther, 49(6):779-788.
  44. Xiao Q. et al. (2014) Inverse association of total and decaffeinated coffee with liver enzymes in NHANES 1999-2010. Hepatol, 10.1002/hep.27367.
  45. Alferink L.J.M. et al. (2017) Coffee and herbal tea consumption is associated with lower liver stiffness in the general population: The Rotterdam Study. J Hepatol, published online ahead of print.
  46. Soleimani D. et al. (2019) Dietary patterns in relation to hepatic fibrosis among patients with non-alcoholic fatty liver disease. Diab, Metab Synd, Obesity, 12:315-324.
  47. Tomic D et al. (2018) Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies. Eur J Gastroenterol Hepatol, 30(10):1103-1115.
  48. Dranoff J.A. (2017) How does coffee prevent liver fibrosis? Biological plausibility for recent epidemiological observations. Hepatol, 60(2):464-467.